HLS Therapeutics Inc.
HLTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $119 | $116 | $103 | $86 |
| - Cash | $11 | $12 | $18 | $17 |
| + Debt | $54 | $56 | $64 | $66 |
| Enterprise Value | $163 | $159 | $149 | $135 |
| Revenue | $14 | $14 | $13 | $16 |
| % Growth | -4.7% | 12.3% | -18.8% | – |
| Gross Profit | $11 | $12 | $10 | $13 |
| % Margin | 81.2% | 82.3% | 81% | 82.7% |
| EBITDA | $4 | $5 | $3 | $5 |
| % Margin | 29.8% | 33.3% | 23.1% | 30.9% |
| Net Income | -$4 | -$3 | -$4 | -$3 |
| % Margin | -29% | -19.3% | -35.1% | -19.5% |
| EPS Diluted | -0.12 | -0.088 | -0.14 | -0.095 |
| % Growth | -36.2% | 37.1% | -47.5% | – |
| Operating Cash Flow | $2 | $5 | $4 | $3 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$0 |
| Free Cash Flow | $2 | $4 | $4 | $3 |